Vertex Pharmaceuticals (MA) Reviews Recent Progress And Announces Upcoming Milestones In The Development Of Multiple Combinations Of Medicines That Target The Underlying Cause Of Cystic Fibrosis

ATLANTA--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today reviewed recent progress and announced upcoming milestones in its efforts to develop multiple combinations of medicines that treat the underlying cause of cystic fibrosis (CF) for the majority of people with the disease. These updates were made in conjunction with the 28th Annual North American Cystic Fibrosis Conference (NACFC), which begins today in Atlanta. The company will webcast an investor presentation from the conference at 6:15 p.m. ET on Friday, October 10. The webcast can be accessed live through Vertex’s website.

Help employers find you! Check out all the jobs and post your resume.